Browse by Phase
Phase 1 / Phase 2 Clinical Trials
Phase 1/2 combined trials evaluate both safety (Phase 1) and preliminary efficacy (Phase 2) in a single study protocol, often used to accelerate early development.
Total Trials
393
Recruiting Now
393
Top Conditions in Phase 1 / Phase 2
Frequently Asked Questions — Phase 1 / Phase 2 Trials
What are combined Phase 1/2 clinical trials?
Phase 1/2 trials are adaptive designs that evaluate both safety (Phase 1 objectives) and preliminary efficacy (Phase 2 objectives) within a single trial protocol. They are commonly used in oncology and rare disease research to accelerate development timelines. Dose escalation occurs in the Phase 1 portion, followed by expansion cohorts at the selected dose in the Phase 2 portion.
Why do sponsors combine Phase 1 and Phase 2?
Combining phases reduces development time and cost, particularly for conditions with high unmet need. For rare diseases or cancer indications, finding sufficient eligible patients can be challenging—a combined design uses the same patient pool more efficiently. Regulatory agencies including the FDA encourage adaptive designs to accelerate evidence generation for serious conditions.
How do I find Phase 1/2 trials I can join?
Phase 1/2 trials listed on ClinicalMetric are sourced from ClinicalTrials.gov and filtered by recruitment status. Each listing shows enrollment status, conditions studied, sponsor, participating sites, and estimated enrollment. Because Phase 1/2 trials often have narrow eligibility criteria, carefully review the protocol and discuss potential participation with your treating physician.
Active Phase 1 / Phase 2 Studies
NCT05773859 Phase 1, Phase 2
Recruiting
NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer
Condition
Epithelial Ovarian Cancer
Enrollment
10 pts
Location
Netherlands
Sponsor
Radboud University Medical Cen
NCT05875168 Phase 1, Phase 2
Recruiting
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
Condition
Advanced Solid Tumor
Enrollment
590 pts
Location
United States, Belgium, Canada
Sponsor
Daiichi Sankyo
NCT07075510 Phase 1, Phase 2
Recruiting
Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell D...
Condition
Plasma Cell Disorder
Enrollment
30 pts
Location
United States
Sponsor
University of Maryland, Baltim
NCT04643418 Phase 1, Phase 2
Recruiting
Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
Condition
Solid Tumor, Unspecified, Adult
Enrollment
81 pts
Location
Taiwan
Sponsor
MegaPro Biomedical Co. Ltd.
NCT04104776 Phase 1, Phase 2
Recruiting
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumor...
Condition
Advanced Solid Tumor
Enrollment
300 pts
Location
United States, France, Italy
Sponsor
Novartis Pharmaceuticals
NCT07451613 Phase 1, Phase 2
Recruiting
Safety and Tolerability Study of Human Neural Stem Cells for Huntington's Diseas...
Condition
Huntington Disease
Enrollment
21 pts
Location
United States
Sponsor
Leslie Thompson
NCT05156060 Phase 1, Phase 2
Recruiting
Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally ...
Condition
Head and Neck Cancer
Enrollment
64 pts
Location
United States
Sponsor
Natalie Lockney
NCT04006808 Phase 1, Phase 2
Recruiting
A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Preven...
Condition
Herpes Zoster
Enrollment
184 pts
Location
Belgium, France, Italy
Sponsor
GlaxoSmithKline
NCT07391813 Phase 1, Phase 2
Recruiting
SNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer
Condition
Patient is Not Suitable for Complete Surgical Resection With a Cytologically or Histologically Confirmed Small Cell Lung Cancer(SCLC)
Enrollment
55 pts
Location
Serbia
Sponsor
SN BioScience
NCT07673809 Phase 1, Phase 2
Recruiting
A Study to Evaluate the Tolerability, Safety and Efficacy of GNR-097 Gene Therap...
Condition
Duchenne Muscular Dystrophy
Enrollment
32 pts
Location
Belarus, Russia
Sponsor
AO GENERIUM
NCT05269316 Phase 1, Phase 2
Recruiting
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Ad...
Condition
Solid Tumor
Enrollment
61 pts
Location
United States, Australia, China
Sponsor
Impact Therapeutics, Inc.
NCT05443126 Phase 1, Phase 2
Recruiting
A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancie...
Condition
NSCLC
Enrollment
265 pts
Location
United States, France, Germany
Sponsor
Ellipses Pharma
NCT07161726 Phase 1, Phase 2
Recruiting
Cocoa to Maximize Exercise Training in Older Adults - The COMET Trial
Condition
Mobility Disability
Enrollment
36 pts
Location
United States
Sponsor
University of Alabama at Birmi
NCT05774704 Phase 1, Phase 2
Recruiting
Curcumin and Retinal Study
Condition
Bioavailability
Enrollment
60 pts
Location
United States
Sponsor
Texas Tech University Health S
NCT06805448 Phase 1, Phase 2
Recruiting
Intraglandular Treatment With Adipose-derived Mesenchymal Stem Cells in Patients...
Condition
Sjorgren's Syndrome
Enrollment
40 pts
Location
Denmark
Sponsor
Rigshospitalet, Denmark
NCT07702890 Phase 1, Phase 2
Recruiting
A Three-part First-in-human Trial to Assess Safety, Tolerability, Pharmacokineti...
Condition
Obesity
Enrollment
188 pts
Location
Germany
Sponsor
Gubra A/S
NCT05533697 Phase 1, Phase 2
Recruiting
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint ...
Condition
Advanced Solid Tumors
Enrollment
361 pts
Location
United States, Australia, Germany
Sponsor
ModernaTX, Inc.
NCT06430385 Phase 1, Phase 2
Recruiting
ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Phar...
Condition
Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome
Enrollment
48 pts
Location
United States, Austria, France
Sponsor
Ionis Pharmaceuticals, Inc.
NCT07612215 Phase 1, Phase 2
Recruiting
Elacestrant in Advanced Triple Positive Breast Cancer
Condition
ER Positive, HER2 Positive Breast Cancer
Enrollment
50 pts
Location
United States
Sponsor
NYU Langone Health
NCT07252050 Phase 1, Phase 2
Recruiting
Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Di...
Condition
Sickle Cell Disease
Enrollment
24 pts
Location
United States
Sponsor
Arkansas Children's Hospital R
NCT06109558 Phase 1, Phase 2
Recruiting
The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC
Condition
Non Small Cell Lung Cancer
Enrollment
120 pts
Location
China
Sponsor
Hunan Province Tumor Hospital
NCT05333250 Phase 1, Phase 2
Recruiting
Modafinil to Improve Fatiguability
Condition
Cancer-related Cognitive Difficulties
Enrollment
40 pts
Location
Canada
Sponsor
Ottawa Hospital Research Insti
NCT05310591 Phase 1, Phase 2
Recruiting
Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children...
Condition
B Acute Lymphoblastic Leukemia
Enrollment
26 pts
Location
France
Sponsor
Assistance Publique - Hôpitaux
NCT06480760 Phase 1, Phase 2
Recruiting
Effects of Carnosine In Patients With Peripheral Arterial Disease Patients
Condition
Peripheral Arterial Disease
Enrollment
144 pts
Location
United States
Sponsor
Shahid Baba
NCT06931990 Phase 1, Phase 2
Recruiting
A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of L...
Condition
Atopic Dermatitis (AD)
Enrollment
24 pts
Location
China
Sponsor
Leadingtac Pharmaceutical (Sha
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology